EP Patent

EP2123637A1 — Novel curcumin derivative

Assigned to Tokyo Institute of Technology NUC · Expires 2009-11-25 · 16y expired

What this patent protects

The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on Aβ aggregation, a degradative effect on Aβ aggregates, an inhibitory effect on β-secretase, and a protective effect on neurons. The novel compound is a compoun…

USPTO Abstract

The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on Aβ aggregation, a degradative effect on Aβ aggregates, an inhibitory effect on β-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R 1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R 2 represents a 1H-indol-6-yl group or the like.

Drugs covered by this patent

Patent Metadata

Patent number
EP2123637A1
Jurisdiction
EP
Classification
—
Expires
2009-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Tokyo Institute of Technology NUC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.